Literature DB >> 21442242

Metabolic assessment of monofocal acute inflammatory demyelination using MR spectroscopy and (11)C-methionine-, (11)C-choline-, and (18)F-fluorodeoxyglucose-PET.

Shunsuke Takenaka1, Jun Shinoda, Yoshitaka Asano, Tatsuki Aki, Kazuhiro Miwa, Takeshi Ito, Kazutoshi Yokoyama, Toru Iwama.   

Abstract

Monofocal acute inflammatory demyelination (MAID), which is observable by CT and MRI as a well-enhanced mass lesion with prominent perifocal edema, is very similar to malignant gliomas radiologically, making differential diagnosis of the two pathologies difficult. The aim of this study was to assess the different metabolic activities between MAID and malignant gliomas by MRS, methionine-PET, choline-PET, and FDG-PET. Six patients with MAID underwent methionine, choline, and FDG-PET, and 4 of the patients also underwent magnetic resonance spectroscopy (MRS). The images obtained from these patients were compared with the corresponding images of 19 anaplastic astrocytomas (AA) and 21 glioblastomas (GBM). The mean choline/creatine ratio of MAID was significantly lower than that of GBM. There were no significant differences in the mean NAA/creatine and lactate/creatine ratios among these pathologies. The methionine T/N ratio of MAID was significantly lower than those of AA and GBM. The choline T/N ratio of MAID was significantly lower than that of GBM. There were no significant differences in the FDG T/N ratios among these pathologies. These results demonstrate that the metabolic activity of MAID significantly differs in part from that of malignant gliomas. Combined PET and MRS neuroimaging examinations may be useful for differential diagnosis of these pathologies.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21442242     DOI: 10.1007/s10014-011-0027-3

Source DB:  PubMed          Journal:  Brain Tumor Pathol        ISSN: 1433-7398            Impact factor:   3.298


  6 in total

Review 1.  Sequential whole-body PET/MR scanner: concept, clinical use, and optimisation after two years in the clinic. The manufacturer's perspective.

Authors:  Antonis Kalemis; Bénédicte M A Delattre; Susanne Heinzer
Journal:  MAGMA       Date:  2012-08-07       Impact factor: 2.310

2.  18F-fluoroethyl-L-tyrosine positron emission tomography for the differential diagnosis of tumefactive multiple sclerosis versus glioma: A case report.

Authors:  Sied Kebir; Florian C Gaertner; Marcus Mueller; Michael Nelles; Matthias Simon; Niklas Schäfer; Moritz Stuplich; Christina Schaub; Michael Niessen; Frederic Mack; Ralph Bundschuh; Susanne Greschus; Markus Essler; Martin Glas; Ulrich Herrlinger
Journal:  Oncol Lett       Date:  2016-02-04       Impact factor: 2.967

Review 3.  Tumefactive Demyelinating Lesions in Multiple Sclerosis and Associated Disorders.

Authors:  Meredith C Frederick; Michelle H Cameron
Journal:  Curr Neurol Neurosci Rep       Date:  2016-03       Impact factor: 5.081

4.  2D-1H proton magnetic resonance spectroscopic imaging study on brain metabolite alterations in patients with diabetic hypertension.

Authors:  Zhen Cao; Bi-Di Ye; Zhi-Wei Shen; Xiao-Fang Cheng; Zhong-Xian Yang; Yan-Yan Liu; Ren-Hua Wu; Kuan Geng; Ye-Yu Xiao
Journal:  Mol Med Rep       Date:  2015-02-05       Impact factor: 2.952

5.  Recurrent Fulminant Tumefactive Demyelination With Marburg-Like Features and Atypical Presentation: Therapeutic Dilemmas and Review of Literature.

Authors:  Aigli G Vakrakou; Dimitrios Tzanetakos; Theodore Argyrakos; Georgios Koutsis; Maria-Eleptheria Evangelopoulos; Elisabeth Andreadou; Maria Anagnostouli; Marianthi Breza; John S Tzartos; Elias Gialafos; Antonios N Dimitrakopoulos; Georgios Velonakis; Panagiotis Toulas; Leonidas Stefanis; Constantinos Kilidireas
Journal:  Front Neurol       Date:  2020-06-30       Impact factor: 4.003

Review 6.  Primary CNS Lymphomas: Challenges in Diagnosis and Monitoring.

Authors:  C Chiavazza; A Pellerino; F Ferrio; A Cistaro; R Soffietti; R Rudà
Journal:  Biomed Res Int       Date:  2018-06-21       Impact factor: 3.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.